 |
 |

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: The WENBIT study by Dr Ebbing and colleagues1 appears to refute the hypothesis of homocysteine as a cardiovascular risk factor. However, some important aspects were not considered in the article's discussion.
Homocysteine is a long-term risk factor. In the Gothenburg study,2 women with a high homocysteine level showed a higher mortality only after a follow-up of more than 15 years. Thus, short-term follow-up after cardiovascular events will probably not be able to demonstrate a benefit of B vitamins.
Furthermore, there seems to be no continuous correlation between homocysteine and cardiovascular risk below a threshold of homocysteine level of 12 µmol/L.2 In prospective studies, only participants in the highest quintile of baseline homocysteine had a significantly increased risk.3 In the WENBIT study, the mean homocysteine level at baseline was so low (approximately 11 µmol/L) that this would not be expected to act as a risk factor at all. . . . [Full Text of this Article]
Johannes Scholl, MD
scholl@preventionfirst.de Prevention First–Private Practice for Preventive Medicine Munich, Germany
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
, , , , , , , , and
JAMA. ;300():795-804.
FULL TEXT
RELATED LETTERS
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
, , and
JAMA. ;300():2852-2852.
FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
, , and
JAMA. ;300():2852-2853.
FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease--Reply
, , and
JAMA. ;300():2853-2854.
FULL TEXT
|